Tumours with miR-346-induction were significantly smaller at end-point versus vehicle-treated tumours (Fig. 6Ciii), showing significantly decreased protein levels of proliferation marker, Ki67, and elevated apoptotic marker, cleaved Caspase-3 (Fig. 6E, Fig S14Fii, v, Fig. S16) Doxycycline-induction of shNORAD significantly repressed xenograft tumour growth, increased survival and reduced end-point tumour volume (Fig. 6D), despite only 20% reduction in NORAD levels (Fig. S14E). The gene discussed is NORAD; the disease is neoplasm.